Skip to main content
TipRanks
Go Ultimate75% OFF

Scinai Immunotherapeutics (SCNI) AI Stock Analysis

351 Followers
SCNI

Scinai Immunotherapeutics

(NASDAQ:SCNI)

Select Model
Rating:41Neutral
Price Target:$0.39â–¼(-4.46% Downside)
Action:reiterated
Date:11/11/26

The score is held down primarily by persistent operating losses, substantial cash burn, weak technical momentum, and funding risk. Revenue growth, improved capitalization, committed orders, and commercial execution initiatives provide meaningful but insufficient offsets.

Positive Factors
CDMO Order GrowthRapid revenue growth and a large increase in committed orders indicate that the expanded CDMO platform is gaining commercial traction. If execution continues, the stronger backlog can improve facility utilization, revenue visibility, customer relationships, and operating leverage over the next several quarters.
Negative Factors
Persistent Operating LossesThe company is expanding revenue while still losing money at both the gross-profit and operating levels, showing that the current business volume does not yet cover its enlarged cost base. Persistent losses could delay self-sustaining profitability and require continued improvements in utilization, pricing, and execution.

Scinai Immunotherapeutics (SCNI) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%SCNI-95.92%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$208.90K
Dividend Yield
―
Average Volume (3M)
2.16M
Price to Earnings (P/E)
0.0
Beta (1Y)
1.36
Revenue Growth
143.06%
EPS Growth
94.98%
Country
US
Employees
45
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Scinai Immunotherapeutics Business Overview & Revenue Model

Company Description

Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range o...

How the Company Makes Money

Publicly available, company-specific detail on Scinai Immunotherapeutics’ current revenue model and recurring revenue streams is not available in the information provided. null

Scinai Immunotherapeutics Earnings Call Summary

Earnings Call Date:Aug 20, 2026(Q2-2026)|% Change Since:-85.25%|Next Earnings Date:May 30, 2019
Earnings Call SentimentNeutral

The call conveys a constructive strategic story: the Recipharm acquisition materially expanded Scinai's capabilities and produced early commercial traction (committed orders, invoicing and a U.S. engagement with ~$650k in post-quarter cash). However, near-term financials show meaningful operating and gross losses and a modest cash balance (~$2.85M), leaving the company reliant on successful conversion of orders, utilization improvements and additional funding. Management emphasizes disciplined R&D spending, use of non-dilutive funding and selective use of the $15M SEPA. Given the balance of promising commercial/strategic progress against short-term liquidity and operating loss challenges, the tone is cautiously optimistic but pragmatic.

Positive Updates

Revenue Growth Year-over-Year
Reported revenue for H1 2026 was approximately $949,000 versus $773,000 in H1 2025, an increase of ~22.8% year-over-year, indicating early commercial traction following the acquisition.

Negative Updates

Operating and Gross Losses
Despite the accounting gain, underlying operations produced a gross loss of approximately $2.37M and an operating loss of approximately $4.6M for H1 2026, reflecting fixed/semi-fixed costs from the expanded CDMO footprint before utilization ramped.

Company Guidance

Management's guidance is focused on commercial execution and capital discipline: they are pursuing approximately $5.0M of CDMO revenue for 2026 and aim to convert ~$3.1M of committed customer orders (≈$1.6M Yavne / ≈$1.5M Jerusalem; ≈$2.1M invoiced as of Aug 10 and ≈$1.0M signed but not yet invoiced) into recognized revenue and higher utilization across Jerusalem and Yavne; liquidity stood at ≈$2.85M cash and restricted cash as of June 30, they received ≈$650k in cash/advances after June 30 from a U.S. clinical manufacturing engagement, and H1 results showed revenue ≈$949k (vs ≈$773k H1 2025), gross loss ≈$2.37M, operating loss ≈$4.6M, and a noncash bargain purchase gain ≈$6.4M that produced net income ≈$1.57M; management plans to emphasize repeat business, non-dilutive funding and selective use of the existing $15M SEPA (post‑effective amendment; advances priced at 97% of VWAP) while prioritizing R&D spend.

Scinai Immunotherapeutics Financial Statement Overview

Summary

Revenue grew strongly, and the balance sheet is moderately leveraged with approximately $10.7 million of equity versus $3.4 million of debt. However, severe operating losses, negative margins, and approximately $7.8 million of TTM free cash flow make financial performance a major weakness.

Income Statement

15Very Negative

Balance Sheet

65Positive

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Dec 2023Mar 2023Dec 2021
Income Statement
Total Revenue3.08M1.31M658.00K000
Gross Profit-3.68M-2.65M-580.00K00-747.65K
EBITDA-6.56M-6.53M-6.99M-2.19M-5.23M-10.32M
Net Income-2.52M-8.31M4.80M-6.50M-5.80M-12.38M
Balance Sheet
Total Assets15.70M11.63M13.45M17.47M27.07M32.04M
Cash, Cash Equivalents and Short-Term Investments1.71M1.66M1.96M4.87M14.07M17.37M
Total Debt3.39M2.27M2.09M20.56M21.54M29.23M
Total Liabilities4.98M3.52M3.47M22.04M28.83M31.05M
Stockholders Equity10.71M8.10M9.98M-4.57M-1.76M982.00K
Cash Flow
Free Cash Flow-7.79M-6.05M-6.35M-10.02M-8.10M-7.57M
Operating Cash Flow-7.55M-6.03M-6.33M-9.38M-7.26M-7.43M
Investing Cash Flow2.53M-24.00K-12.00K-637.00K-836.00K-139.00K
Financing Cash Flow5.48M5.77M3.44M1.09M6.78M21.43M

Scinai Immunotherapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.40

Price Trends

50DMA1.06Negative
100DMA1.81Negative
200DMA3.96Negative

Market Momentum

MACD-0.19Negative
RSI25.07Positive
STOCH16.03Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNI, the sentiment is Negative. The current price of 0.40 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 1.06, and below the 200-day MA of 3.96, indicating a bearish trend. The MACD of -0.19 indicates Negative momentum. The RSI at 25.07 is Positive, neither overbought nor oversold. The STOCH value of 16.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCNI.

Scinai Immunotherapeutics Risk Analysis

Scinai Immunotherapeutics disclosed 78 risk factors in its most recent earnings report. Scinai Immunotherapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Scinai Immunotherapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SCNI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GTBPGTBP43Neutral$7.29M-0.03-443.08%――75.09%
SCNISCNI41Neutral$546.84K0.00-23.86%―143.06%94.98%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%SCNIGTBPADTXCEROPBMCDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SCNI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SCNIScinai Immunotherapeutics Ltd. Sponsored Adr0.40-9.32-95.85%
GTBPGt Biopharma, Inc.3.54-12.85-78.43%
ADTXAditxt, Inc.0.04-881.24-100.00%
CEROCero Therapeutics Holdings, Inc.0.01-0.05-83.61%
PBMPsyence Biomedical Ltd.2.83-14.61-83.77%
CDTCdt Equity Inc.0.38-261249.59-100.00%

Scinai Immunotherapeutics Corporate Events

Scinai Immunotherapeutics Announces ADS Ratio Change Effective November 19

Nov 17, 2026

On November 17, 2026, Scinai Immunotherapeutics announced that, effective November 19, its ADS-to-ordinary-share ratio would change from one ADS representing 40,000 ordinary shares to one representing 160,000, having the effect of a one-for-four reve...

Scinai Immunotherapeutics Reports 167% Revenue Growth as CDMO Expands

Nov 9, 2026

Scinai Immunotherapeutics is a biopharmaceutical company combining a contract development and manufacturing organization (CDMO) with an immunology-focused therapeutic development platform, serving drug-development and clinical-supply markets. On Nov....

Scinai Immunotherapeutics Extends Cash Runway on New CDMO Deal and October Financing

Oct 20, 2026

On October 20, 2026, Scinai Immunotherapeutics reported that a new CDMO agreement with a U.S.-based Nasdaq-listed biopharmaceutical client and recently completed equity financings have significantly expanded its contracted business and strengthened l...

Scinai Immunotherapeutics Closes $4 Million Private Placement and Warrant Deal

Oct 16, 2026

On October 16, 2026, Scinai Immunotherapeutics closed a $4.0 million financing, combining a private placement of American Depositary Shares and an inducement for immediate exercise of existing warrants, which also generated new Series A-1 warrants. T...

Scinai Immunotherapeutics Secures $4 Million via Private Placement and Warrant Inducement

Oct 15, 2026

On October 13, 2026, Scinai Immunotherapeutics entered into a securities purchase agreement with an existing institutional life sciences investor for a private placement of 2,458,334 American Depositary Shares or pre-funded warrants, plus Series A-1...

Scinai Immunotherapeutics Secures $5.1 Million CDMO Deal, Tripling Committed Orders

Oct 13, 2026

Scinai Immunotherapeutics announced on October 13, 2026 that its subsidiary Scinai Biopharma Services has signed a definitive development and clinical manufacturing agreement worth approximately $5.1 million in committed base service fees with a U.S....

Scinai Immunotherapeutics Restores Nasdaq Minimum Bid Price Compliance

Sep 21, 2026

On September 21, 2026, Scinai Immunotherapeutics announced that Nasdaq has confirmed the company regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), closing a months-long listing risk. The decision followed...

Scinai Shifts Capital to NanoAb Platform and CDMO Growth After Ending PC111 Deal

Sep 8, 2026

On September 8, 2026, Scinai Immunotherapeutics announced it had allowed its option and license agreements with PinCell regarding the preclinical program PC111 to expire on August 31, 2026, ending its involvement without securing new funding. The com...

Scinai Highlights First-Half CDMO Expansion and Recipharm Israel Gain in August 2026 Update

Aug 26, 2026

In a business update released on August 24, 2026, Scinai Immunotherapeutics reported growing momentum in its CDMO arm, with committed customer orders reaching about $3.1 million as of August 16, 2026 and an expanded clinical manufacturing and CMC pro...

Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance

Aug 19, 2026

On August 19, 2026, Scinai Immunotherapeutics announced that, effective August 21, 2026, it will change the ratio of its American Depositary Shares so that one ADS will represent 40,000 ordinary shares instead of 4,000, a move that functions as a one...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026